Genedata Profiler®は、業界を牽引するバイオファーマ企業とのコラボレーションを通して開発されており、オミクスベースのトランスレーショナル/クリニカルリサーチを効果的に進め、製品の早期上市に繋げたい多くの企業にとって、理想的な選択肢です。
This partnership provides us with innovative approaches to drive the integration of biomarker data within and across our clinical programs including the digitalizing of translational workflows associated with clinical studies.
With the scientific support of Genedata and its Genedata Profiler software, Egis has developed the PREDYSTIC® Infliximab RA Kit to guide the treatment of RA patients, allowing therapies to be matched to the patients who will derive true benefits from treatment.
The Genedata Profiler platform is used productively in a validated environment and is helping to democratize access to integrated data in the translational research and clinical settings.
Working closely with Genedata, we have generated a digital biomarker research platform that will enable Merck scientists to better utilize clinical and translational data to generate innovative ideas for new biomarkers and drug targets.
We are pleased to have found a reliable partner who provided us with expert knowledge in big multi-omics data analysis to accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions.
We chose Genedata Profiler because it is the end-to-end enterprise software able to harmonize our dispersed data analysis pipelines, enhancing our capacity to analyze large amounts of high-dimensional ‘omics data emerging from our rapidly growing number of translational and clinical research projects.
As we expect our clinical and pre-clinical programs and pipeline to continue to grow, we look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients.
